Sugi Predict

Sugi Predict / Compounds / SCHEMBL10079339

SCHEMBL10079339

SCHEMBL10079339

O=C(O)CCOCCOCCN1C(=O)C=CC1=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 6/20 0.71
▸ PTGS1 P23219 6/20 0.56
▸ PTGS2 P35354 6/20 0.56
▸ FAAH O00519 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ HPGD P15428 2/20 0.41
▸ PKM P14618 2/20 0.41
▸ HSP90AA1 P07900 1/20 0.41
▸ TLR9 Q9NR96 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ XBP1 P17861 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ GPR35 Q9HC97 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13733359 1.00 MGLL (0.71) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL5208692 1.00 MGLL (0.71) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL22311909 1.00 MGLL (0.71) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL16933147 1.00 MGLL (0.71) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL27420754 1.00 MGLL (0.71) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL15215618 1.00 MGLL (0.71) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL17732171 1.00 MGLL (0.71) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL5828798 0.98 MGLL (0.68) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL18157046 0.90 PTGS1 (0.62) MGLLPTGS1PTGS2FAAHALDH1A1
SCHEMBL10126653 0.90 MGLL (0.67) MGLLPTGS1PTGS2FAAHALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719381-A1 LIGAND-POLAR DRUG CONJUGATES Tripartite Therapeutics Inc. (TW) 2026-04-08 — — EP disclosed
US-12576156-B2 Compound comprising self-immolative group and ligand-drug conjugate comprising same TRIOAR, INC. (KR) 2026-03-17 — — US disclosed
EP-4545096-A1 COMPOUND COMPRISING SELF-IMMOLATIVE GROUP AND LIGAND-DRUG CONJUGATE COMPRISING SAME Trioar, Inc. (KR) 2025-04-30 — — EP disclosed
EP-4545097-A1 NOVEL LINKER COMPOUND AND LIGAND-DRUG CONJUGATE THEREFOR Trioar, Inc. (KR) 2025-04-30 — — EP disclosed
US-20250121072-A1 COMPOUND COMPRISING SELF-IMMOLATIVE GROUP AND LIGAND-DRUG CONJUGATE COMPRISING SAME TRIOAR, INC. (KR) 2025-04-17 — — US disclosed
US-20250114441-A1 POLYMERIC VACCINE FOR OPIOID ADDICTION THE JOHNS HOPKINS UNVERSITY 2025-04-10 — — US disclosed
CN-119522110-A Novel linker compounds and ligand-drug conjugates thereof 特里奥尔株式会社 2025-02-25 — — CN disclosed
CN-119451701-A Compounds comprising self-destructing groups and ligand-drug conjugates comprising the same 特里奥尔株式会社 2025-02-14 — — CN disclosed
US-20250032635-A1 LIGAND-POLAR DRUG CONJUGATES TRIPARTITE THERAPEUTICS INC. (TW) 2025-01-30 — — US disclosed
EP-4460330-A1 CONJUGATES, COMPOSITIONS AND METHODS OF USE Virtuoso Binco, Inc. (US) 2024-11-13 — — EP disclosed
WO-2015095301-A2 CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF IRM LLC (BM) 2015-06-25 — — WO disclosed
WO-2015095301-A2 CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF IRM LLC (BM) 2015-06-25 — — WO disclosed
US-8722622-B2 FGF21 conjugates and anti-diabetic uses thereof COVX TECHNOLOGIES IRELAND, LIMITED (IE) 2014-05-13 — — US disclosed
US-8722622-B2 FGF21 conjugates and anti-diabetic uses thereof COVX TECHNOLOGIES IRELAND, LIMITED (IE) 2014-05-13 — — US disclosed
WO-2013093720-A2 ANTI-DIABETIC COMPOUNDS PFIZER INC. (US) 2013-06-27 — — WO disclosed
US-20130164310-A1 ANTI-DIABETIC COMPOUNDS COVX TECHNOLOGIES IRELAND LIMITED 2013-06-27 — — US disclosed
US-20130164310-A1 ANTI-DIABETIC COMPOUNDS COVX TECHNOLOGIES IRELAND LIMITED 2013-06-27 — — US disclosed
US-20120282279-A1 Anti-Diabetic Compounds COVX TECHNOLOGIES IRELAND LIMITED (IE) 2012-11-08 — — US disclosed
US-20120282279-A1 Anti-Diabetic Compounds COVX TECHNOLOGIES IRELAND LIMITED (IE) 2012-11-08 — — US disclosed
WO-2012059873-A2 ANTI-DIABETIC COMPOUNDS COVX TECHNOLOGIES IRELAND, LTD. (IE) 2012-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12576156-B2 Compound comprising self-immolative group and ligand-drug conjugate comprising same SLC7A1, CLTC, MSR1 MGLL 276/4885PTGS1 2159/4885PTGS2 2922/4885
US-20250121072-A1 COMPOUND COMPRISING SELF-IMMOLATIVE GROUP AND LIGAND-DRUG CONJUGATE COMPRISING SAME CD44, MSN, EPCAM MGLL 425/4885PTGS1 2444/4885PTGS2 2815/4885
US-20120282279-A1 Anti-Diabetic Compounds GLP1R, FGF2, FGFR1 MGLL 1667/4885PTGS1 1694/4885PTGS2 1823/4885
US-20250032635-A1 LIGAND-POLAR DRUG CONJUGATES CD274, SELPLG, PDCD1LG2 MGLL 2599/4885PTGS1 3110/4885PTGS2 3705/4885
US-20250114441-A1 POLYMERIC VACCINE FOR OPIOID ADDICTION OPRM1, OPRK1, OPRL1 MGLL 1411/4885PTGS1 2273/4885PTGS2 2124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.